OBI Pharma, Inc

Sourced facts

• Antibody-drug conjugate program OBI-902: ClinicalTrials.gov lead sponsor (1 trial) · clinicaltrials.gov/study/NCT07124117 · checked Oct 20, 2026
• Antibody-drug conjugate program OBI-992: ClinicalTrials.gov lead sponsor (1 trial) · clinicaltrials.gov/study/NCT06480240 · checked Oct 20, 2026
• “We focus on developing next-generation antibody-drug conjugates (ADCs), targeting mainstream cancer therapies.” · www.obipharma.com · checked Oct 20, 2026